

Role of Phosphoglucosyltransferase of *Bordetella bronchiseptica* in Lipopolysaccharide Biosynthesis and Virulence

NICHOLAS P. WEST,¹ HEIDRUN JUNGNTZ,² JOHN T. FITTER,^{1†} JASON D. MCCARTHUR,¹
CARLOS A. GUZMÁN,² AND MARK J. WALKER^{1*}

Department of Biological Sciences, University of Wollongong, New South Wales, Australia,¹ and Department of Microbial Pathogenicity and Vaccine Research, Division of Microbiology, GBF-National Research Centre for Biotechnology, Braunschweig, Germany²

Received 8 November 1999/Returned for modification 3 January 2000/Accepted 5 May 2000

The phosphoglucosyltransferase (PGM)-encoding gene of *Bordetella bronchiseptica* is required for lipopolysaccharide (LPS) biosynthesis. An insertion mutant of the wild-type *B. bronchiseptica* strain BB7865 which disrupted LPS biosynthesis was created and characterized (BB7865*pgm*). Genetic analysis of the mutated gene showed it shares high identity with PGM genes of various bacterial species and forms part of an operon which also encompasses the gene encoding phosphoglucose isomerase. Functional assays for PGM revealed that enzyme activity is expressed in both *bvg*-positive and *bvg*-negative strains of *B. bronchiseptica* and is substantially reduced in BB7865*pgm*. Complementation of the mutated PGM gene with that from BB7865 restored the wild-type condition for all phenotypes tested. The ability of the mutant BB7865*pgm* to survive within J774.A1 cells was significantly reduced at 2 h (40% reduction) and 24 h (56% reduction) postinfection. BB7865*pgm* was also significantly attenuated in its ability to survive *in vivo* following intranasal infection of mice, being effectively cleared from the lungs within 4 days, whereas the wild-type strain persisted at least 35 days. The activities of superoxide dismutase, urease, and acid phosphatase were unaffected in the PGM-deficient strain. In contrast, the inability to produce wild-type LPS resulted in a reduced bacterial resistance to oxidative stress and a higher susceptibility to the antimicrobial peptide cecropin P.

Of the *Bordetella* genus, *Bordetella bronchiseptica* is the principle effector of respiratory disease in a wide range of mammals (16). However, *B. bronchiseptica* only rarely infects humans (18, 46, 54). *B. bronchiseptica* is credited as being the primary etiological component of tracheobronchitis in dogs from as early as 1910 (14) and is known to be associated with atrophic rhinitis, a common bronchial affliction of swine (40). *B. bronchiseptica* infections are mediated by the controlled expression of a number of virulence factors, such as the adhesin filamentous hemagglutinin (10) and the toxins adenylate cyclase hemolysin and dermonecrotic toxin (7, 50). The regulation of these virulence determinants is under the control of a two-component signal transduction system known as the *Bordetella* virulence gene (*bvg*) locus. Genetic control is observed in response to environmental conditions such as temperature and chemical modulators, i.e., sulfate anions (1, 27).

Lipopolysaccharide (LPS) is a highly toxic and immunogenic molecule that constitutes a major component of the cell membranes in gram-negative bacteria (37). LPS has now emerged as having an integral role in the infection process, being responsible for resistance to serum, antibiotics (39), and naturally occurring antimicrobial peptides termed defensins (5). The role of LPS as an important adhesin molecule also seems likely; however, its role in the pathogenesis process still remains largely unknown. It has recently been stated that the LPS of some strains of *B. bronchiseptica* is regulated by the *bvg* system (48).

The LPS of the related bacterium *Bordetella pertussis* dis-

plays a structure that generally typifies that of nonenteric bacteria. This consists of a lipid A region anchored in the cell membrane, being linked to a branched oligosaccharide domain constituting the core, by a single keto-deoxyoctulosonic acid (2, 17, 48). These glycolipids lack long repeating oligosaccharide units as are found in the *Enterobacteriaceae* and are therefore sometimes termed lipooligosaccharides (37). *B. bronchiseptica* and *Bordetella parapertussis* do, however, produce an O-antigen of a single sugar polymer, consisting of 2,3-dideoxy-di-*N*-acetylgalactosaminuronic acid (4, 13). There is considerable variation in glycolipid structure within the genus *Bordetella* (48).

Two distinct bands, i.e., band A and band B (35), are evident upon electrophoresis of purified *B. pertussis* LPS. Band B consists of the core region of the molecule, whereas the slower-migrating band A is this same core with the addition of a distal trisaccharide comprised of *N*-acetylglucosamine, *N*-acetyl-*N*-methylfucosamine, and 2,3-di-deoxy-2,3-di-*N*-acetylmannosaminuronic acid (2). It is understood that all three elements of the LPS molecule, i.e., lipid A, core, and O-antigen, are required for virulence of *Escherichia coli* (23). Viability of the organism is not necessarily disrupted by the absence of the O-antigen or several of the core sugars, but the keto-deoxyoctulosonic residues of the core and the lipid A are essential for growth (23). So important is the lipid A component of LPS to the viability of the cell that it has been described as a suitable pharmaceutical target (34).

A gene cluster for LPS production in *B. pertussis* and *B. bronchiseptica* has been identified, and the probable functions of the gene products have been discussed (2, 36); however, the role of LPS in the *B. bronchiseptica* infection process remains largely undescribed. We describe here an LPS mutant of *B. bronchiseptica*, designated BB7865*pgm*, resulting from an insertion in the phosphoglucosyltransferase (PGM)-encoding gene. This gene appears to be organized into an operon with the

* Corresponding author. Mailing address: Department of Biological Sciences, University of Wollongong, New South Wales, Australia 2522. Phone: 0061-242213439. Fax: 0061-242214135. E-mail: mwalker@uow.edu.au.

† Present address: Endocrine Unit, Department of Medicine, John Hunter Hospital, Newcastle, New South Wales, Australia.

phosphoglucose isomerase (PGI)-encoding gene. Regulation of *pgm* is constitutive and is therefore controlled independently of the *bvg* system. Loss of PGM activity due to insertional mutation of the gene resulted in a truncation of the LPS. Resistance to oxidative stress was reduced in the mutants as was the ability to resist cecropin P. Finally, BB7865*pgm* was unable to survive within the mouse macrophage-like cell line J774.A1 or colonize mouse lungs following intranasal inoculation.

MATERIALS AND METHODS

Bacterial strains, plasmids, and growth conditions. *B. bronchiseptica* wild-type strain BB7865 and its isogenic *bvg*-negative derivative BB7866 have been characterized in a previous study (33). *E. coli* strain SM10λpir (32) containing pUTmini-Tn5 *lacZ*I (11) was used in mutagenesis experiments. *E. coli* JM109 (55) was used in standard cloning experiments while *E. coli* 294 Rif^r (51) was used for cosmid cloning. *B. bronchiseptica* strains were grown on Bordet Gengou (BG) agar (Difco) containing defibrinated horse blood (10%, vol/vol) and Stainer and Scholte medium (SS-X) (45) or a modulating version of SS-X containing 40 mM MgSO₄ replacing NaCl (SS-C). Liquid cultures were also grown in SS-X or SS-C. *E. coli* strains were grown on Z agar (51) or in LB broth (41). The following antibiotics were used at the indicated concentrations: cephalixin, 50 μg/ml; kanamycin, 50 μg/ml; ampicillin, 100 μg/ml; rifampin, 100 μg/ml; nalidixic acid, 50 μg/ml; trimethoprim, 50 μg/ml. Isopropyl-β-D-galactopyranoside (IPTG) (0.04 mM) and 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside (X-Gal) (0.004%, wt/vol) were used where appropriate.

Mini-transposon mutagenesis. Conjugation between *B. bronchiseptica* BB7866 and the donor *E. coli* SM10λpir containing the suicide plasmid (pUTmini-Tn5 *lacZ*I) was performed. Equal amounts of each bacterial strain were mixed in 0.7% saline and plated onto BG agar. Transconjugants were selected from the resultant growth on SS-X at 37°C containing cephalixin, kanamycin, X-Gal, and IPTG.

In vivo chromosome transfer. The method by which the mini-transposon was transferred from BB7866*pgm* to the homologous location on the wild-type chromosome (BB7865*pgm*) was that described by Smith and Walker (44). *E. coli* Q358(pR715::Tn813) was mated with BB7866*pgm*. This resulted in the plasmid being introduced into BB7866*pgm*. A permanent cointegration of the plasmid into the chromosome occurred, catalyzed by the transposase encoded by Tn813. This recombinant strain of BB7866*pgm* (Tp^r Km^r) was then conjugally mated with BB7865 (Nal^r Rif^r). Chromosome transfer is then promoted by the integrated *tra* genes of pR751, and the recipient strain thus received the original Km^r cassette following homologous recombination.

DNA manipulations. Plasmid DNA was extracted from host cells using mid-prep columns in accordance with manufacturer's instructions (Qiagen). Chromosomal DNA was extracted according to the method of Priefer et al. (38). Restriction endonuclease digestion and agarose gel electrophoresis were conducted using standard methods (41). Cosmid cloning was achieved via the packaging of recombinant cosmids (pHC79) (21) containing chromosomal DNA fragments into lambda phage Max Plax kits (Epicentre Technologies) and subsequent transduction into *E. coli* 294 Rif^r cells. Desired clones were selected and screened by colony hybridization. Chromosomal DNA for Southern hybridization was transferred to positively charged nylon membranes by way of alkaline transfer. Probe DNA was either digoxigenin labeled (Roche) or radiolabeled with [α -³²P]dATP using a nick translation kit (Gibco BRL). Blots were probed under stringent conditions (65°C hybridization). Automated DNA sequencing was performed on plasmid DNA with a Perkin Elmer ABI Prism 377 DNA sequencer. Reactions were performed with Perkin Elmer BigDye terminator cycle sequencing ready reaction mix. Contiguous sequences were constructed using AutoAssembler software (Perkin-Elmer) and aligned with sequences in the GenBank database located at the Australian National Genomic Information Service by utilizing the Blastp algorithm.

PGM and phosphomannomutase (PMM) assays. Crude lysates were prepared from the strains to be tested for mutase activity using the modified method from Sandlin and Stein (42). Cultures of the strains were grown in either SS-X at 37°C or SS-C at 25°C to late logarithmic phase and then centrifuged. The resultant pellets were resuspended in 10 ml of sonication buffer (50 mM MOPS [morpholinepropanesulfonic acid], pH 7.0; dithiothreitol, 1 mM; EDTA, 3 mM). The cells were again pelleted and resuspended in 1 ml of sonication buffer and frozen at -80°C. The cells were immediately thawed and sonicated five times at maximum output for 15 s per burst (Branson Sonifier 250) and allowed to cool on ice between bursts. The sonicated sample was centrifuged at 68,000 × g for 20 min to remove cellular debris. The resulting supernatant is the crude lysate used in both mutase assays and was stored at -80°C until required. Protein concentration of the crude lysates were determined in triplicate with a standard Bradford reagent assay (Sigma). PGM and PMM activities were determined essentially as previously described (25, 42). Specific activities were expressed as milliunits per milligram of protein, where 1 μmol of NADP (substrate) is reduced to NADPH (product) in 1 min by 1 U of enzyme. NADPH production was calculated from its molar extinction coefficient of 6,220. Lysates were tested in duplicate, and three independent lysates were prepared.

LPS extraction. Cells were grown to late log phase in SS-C at 25°C or SS-X at 37°C to an A₅₆₀ of 1.0 and concentrated to A₅₆₀ 1.5 in phosphate-buffered saline (PBS). The resultant cell pellet from 500 μl of sample was resuspended in 100 μl of distilled H₂O. An equal volume of 2× sample buffer (6% sodium dodecyl sulfate; 6% 2-mercaptoethanol; 10 mM dithiothreitol; 46% glycerol; 60 mM Tris, pH 8.0; 0.1% bromophenol blue) was added, and the samples were boiled for 10 min. Protein was digested by the addition of proteinase K to a final concentration of 50 μg/ml at 37°C overnight. Samples were again boiled for 10 min, and a second volume of proteinase K, equal to the first, was added and incubated at 55°C for 3 h. LPS samples were stored at -20°C until required. LPS profiles were determined by Tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Gels of 16.5% were assembled and electrophoresis was performed as described by Lesse et al. (28). LPS was visualized by oxidative silver staining (47).

Complementation of *pgm*. The mini-transposon insertion into BB7865*pgm* was complemented by the conjugal transfer into BB7865*pgm* of plasmid pBBR1MCS-4 (26), which harbored a 1.5-kb *Sac*II fragment containing the complete *pgm* gene of BB7865. This plasmid was designated pBBR1MCS-4/*pgm*⁺.

Resistance to oxidative stress. A disk diffusion assay was utilized to determine sensitivity to paraquat (methyl viologen; Sigma) (22). Approximately 10⁶ cells of BB7865, BB7866, BB7865*pgm*, and BB7866*pgm* were plated onto SS-X or SS-C. A filter with a pore size of 0.22 μm, presoaked in 10 mM paraquat, was placed onto each plate, and this was followed by incubation at 30 or 37°C. Sensitivity to paraquat was measured by the zone of inhibition surrounding the disk. The zone was measured in two axes, and the mean values were calculated.

SOD, acid phosphatase, and urease assays. For superoxide dismutase (SOD) assays, sonicated cell samples (100% output; four 15-s bursts) were cleared by centrifugation (12,000 × g for 2 min). A total of 115 μg of protein from each sample was loaded onto an 8% native polyacrylamide gel and electrophoresed according to standard procedures (52). Nitroblue tetrazolium was used to reveal regions of enzyme activity as outlined by Beauchamp and Fridovich (6). Acid phosphatase and urease activities were determined as previously described (22, 24, 31).

Cecropin P radial diffusion and liquid killing assays. The sensitivity of the mutant strains to cecropin P, a bioactive peptide, was tested. Radial diffusion assays were performed essentially as described previously (5). Bacteria were cultured on BG agar before being resuspended to a final optical density of 0.2 at A₆₀₀ in SS-C or SS-X. Low-gelling-temperature agarose (1%) in either SS-X or SS-C was prepared and when cool was supplemented with bovine serum albumin (final concentration, 0.15%). To 10-ml aliquots, 200-μl aliquots of the cell suspensions were added and allowed to set in a standard 90-mm-diameter petri dish. Cecropin P (5 μg; 1 μg/μl in H₂O; Sigma) was added to 3-mm-diameter wells made in the agarose. Following incubation at room temperature for 4 h, the plates were transferred to 37°C (SS-X plates) until zones were clearly visible. For liquid killing assays, BB7865 and BB7865*pgm* were cultured on SS-X at 37°C and suspended in PBS. Equal volumes of the cell suspension and cecropin P were combined, giving a final peptide concentration of 50 μg/ml. Following 1.5 h of incubation at 37°C, serial dilutions were performed on BB7865 and BB7865*pgm*, with and without cecropin P; plated onto SS-X; and incubated at 37°C.

Tissue culture. The mouse macrophage-like cell line J774.A1 (ATCC TIB 67) was maintained in Dulbecco's modified Eagle medium supplemented with 10% fetal calf serum (vol/vol) and 5 mM glutamine in an atmosphere containing CO₂ (5%, vol/vol) at 37°C. Approximately 5 × 10⁶ cells were seeded per well in 24-well tissue culture plates, incubated for 18 h, and then washed twice with complete medium. For invasion assays the method essentially followed that described by Guzmán et al. (19). The results reported are mean values of three independent assays with standard deviations. Incubation of *B. bronchiseptica* bacteria, resuspended to an optical density equal to that used in the invasion assays in Dulbecco's modified Eagle medium supplemented with gentamicin at 50 mg/ml for 2 h resulted in >6 orders of magnitude of reduction in CFU.

Murine respiratory infection model. Female BALB/c mice at 6 to 10 weeks of age were used as a model of in vivo respiratory infection by *B. bronchiseptica*. Following treatment with Ketamine (50 mg/kg) and Xylazine (10 mg/kg) in sterile PBS, two 12.5-μl aliquots of a bacterial suspension were delivered intranasally to each mouse via an air-displacement pipette and the mouse was allowed to recover. The total number of viable bacteria administered was approximately 10⁵ cells. At each time point four mice from each group were sacrificed and their lungs were removed aseptically. Lungs were homogenized in sterile physiological saline, and appropriate dilutions were plated onto nutrient agar to determine the number of viable bacteria present in the lungs.

Statistics. The results tested for statistical significance were subjected to Student's *t* test. Differences were considered significant if *P* was ≤0.05.

Nucleotide sequence accession number. The nucleotide sequence data for PGM and PGI have been submitted to the GenBank database under the accession number AF171632.

RESULTS

Identification of a novel LPS genetic locus in *B. bronchiseptica*. A mini-Tn5 mutant of the *Bvg*S mutant strain BB7866 was produced (designated BB7866*pgm*) that demonstrated an in-




FIG. 1. Genetic organization and sequence homology of *pgm*. (A) Spatial orientation of the operon from *B. bronchiseptica* containing *pgm* and *pgi*. The equivalent genes were found to exist in *B. pertussis* in the same orientation and with high DNA sequence homology (98.6 and 99.3%, respectively). A gene downstream of *B. pertussis* *pgi* was located and shown to have the highest homology with other galactosyl transferases. The dashed line indicates the fragment of DNA cloned into pBBR1MCS-4 (26) and thereafter utilized for complementation of BB7865 *pgm*. Arrows indicate the direction of transcription. Arrowheads indicate putative promoter sequences. (B) ClustalW alignment of *B. bronchiseptica* (Bbro) *pgm* gene and the following homologous sequences (*pgm* and *pmm*) (abbreviations and accession numbers are given in parentheses): *Neisseria meningitidis* *pgm* (Nmen; P40391), *N. gonorrhoeae* *pgm* (Ngon; P40390), *P. aeruginosa* *pmm* (Paer; P26276), *Azospirillum brasilense* *pmm* (Abra; P45632), and *Prochlorothrix hollandica* *pmm* (Phol; U23551). Identical residues are depicted by dots. Dashes indicate gaps introduced in the amino acid sequence for optimal alignment.

ability to synthesize a complete LPS molecule, as demonstrated by oxidative silver staining of LPS extracts. Initial DNA sequence data obtained from a cosmid clone positive for the mini-Tn5 in Southern blots (data not shown) allowed the production of PCR primers adjacent to the insertion site. These primers enabled the amplification of a 300-bp gene fragment

which was utilized to probe a BB7865 cosmid library. The result of these investigations, following cosmid cloning and subcloning, was a 3.4-kb *NorI* fragment shown to contain a complete gene (Fig. 1A) with an amino acid sequence identity of 55% (72% similarity) with the PGM gene from *Neisseria gonorrhoeae* (Fig. 1B). The PGM gene was shown via Southern




FIG. 2. Characterization of the *pgm* insertion mutation. (A) The mini-Tn5 insertion (5.0 kb) was found to have occurred 604 bp downstream of the *pgm* methionine start codon. (B) Southern blot analysis of *pgm* mutants and other *Bordetella* spp. utilizing the 300-bp PCR fragment (PCR-1), amplified adjacent to the mini-transposon insertion (see panel A). The *pgm* gene exists in an *Eco*RI fragment of 8.4 kb. An *Eco*RI site located on the transposon results in a restriction fragment 539 bp shorter than that of the wild type. Lane 1, BB7865; lane 2, BB7866; lane 3, BB7865*pgm*; lane 4, BB7866*pgm*; lane 5, *B. pertussis*; lane 6, *B. parapertussis*; lane 7, *B. avium*.

blotting to hybridize with DNA fragments of *B. pertussis* and *B. parapertussis* but not with *Bordetella avium* (Fig. 2). Separated by just 10 bp and downstream of the PGM-encoding gene, a second open reading frame was identified which exhibits high homology with the PGI gene from several organisms. These two genes appear to be organized into an operon (Fig. 1A) based on their spatial organization and the absence of an intervening promoter-like sequence. PGI is also found in a similar genetic organization in *B. pertussis* and shares 99.3% nucleotide sequence homology with the *B. bronchiseptica* *pgi* gene as sequenced thus far (the *B. pertussis* genome is found on line at http://www.sanger.ac.uk/Projects/B_pertussis/). This operon has not been previously described in *Bordetella*. An open reading frame located downstream of the *pgi* gene from *B. pertussis* has been identified as encoding a possible galactosyl transferase; however, this gene is not included within the *pgm* operon. The identical gene was mutated in BB7865, the parental strain of BB7866, by way of an in vivo chromosome transfer technique (44). This allowed for the effects of such a mutation to be observed in a *bvg*-positive background. The resultant mutant was designated BB7865*pgm*.

Analysis of PGM enzyme activity from BB7865, BB7866, and their respective *pgm*-deficient mutants. PGM assays were performed to determine the level of enzyme activity in parental and mutant strains. These assays demonstrate that the muta-

tion eliminates the ability to produce functional enzyme, as BB7865*pgm* and BB7866*pgm* are shown to have a PGM activity below the detection limits of the assay (i.e., <2 mU/mg). This was shown to be statistically significant ($P \leq 0.01$) for strains grown in either SS-C at 25°C or SS-X at 37°C (Table 1). PMM assays were also performed, as the mutated gene also shared high amino acid homology to PMM from *Pseudomonas aerugi-*

TABLE 1. Specific activities of PGM and PMM in *B. bronchiseptica* wild-type and mutant strains^a

| Strain | Sp act (mU/mg) of enzyme under condition: | | | |
|---|---|-------------|-------------|-------------|
| | PGM | | PMM | |
| | SS-C, 25°C | SS-X, 37°C | SS-C, 25°C | SS-X, 37°C |
| BB7866 | 7.37 ± 0.39 | 6.3 ± 0.32 | 10.9 ± 1.1 | 6.36 ± 0.3 |
| BB7866 <i>pgm</i> | 1.9 ± 0.45 | 0.29 ± 0.13 | 1.75 ± 0.33 | 1.14 ± 0.06 |
| BB7865 | 7.17 ± 0.23 | 6.26 ± 0.28 | 8.12 ± 0.77 | 6.4 ± 0.4 |
| BB7865 <i>pgm</i> | 0.46 ± 0.3 | 0.81 ± 0.23 | 1.31 ± 0.55 | 0.9 ± 0.36 |
| BB7865 <i>pgm</i> (pBBR1MCS-4/ <i>pgm</i> ⁺) | 9.1 ± 0.83 | 7.75 ± 1.7 | 11.1 ± 0.42 | 7.2 ± 1.12 |

^a Assays were conducted in triplicate for cells grown under modulating and nonmodulating conditions. Assays were performed with independent lysates on three occasions. Values shown are means ± standard errors of the means.




FIG. 3. LPS phenotypes and biosynthesis pathway. (A) Electrophoretic profiles of LPS extracted from BB7865 (lanes 1 and 5), BB7866 (lanes 2 and 6), BB7865pgm (lanes 3 and 7), and BB7866pgm (lanes 4 and 8); lanes 9 and 10 contain the complemented mutant, BB7865pgm (pBBR1MCS-4/pgm⁺). Strains represented in lanes 1 to 4 and 9 were cultured in SS-C at 25°C, whereas those shown in lanes 5 to 8 and 10 were cultured in SS-X at 37°C. O-antigen and core band A and B are indicated to the left. (B) Biosynthesis of nucleotide sugars via *pgm* and *pgi* for production of LPS. (Modified from reference 56 with permission of the publisher.)

nosa. Similar results were obtained for this enzyme, with PGM mutants again displaying low levels of activity, whereas the wild type expressed levels closer to 8.12 mU/mg. Complementation of BB7865pgm with the wild-type *pgm* gene restored PGM and PMM activity to levels observed in BB7865. It is of interest that PGM is known to be a bifunctional enzyme (42) capable of using either glucose or mannose as a substrate. Mannose, however, is not reported as a component of the *B. pertussis* LPS (3); it therefore seems likely that the affected enzyme acts as PGM in *B. bronchiseptica*.

Electrophoretic profiles of LPS extractions clearly demonstrate the physical alterations caused by the mutation of PGM (Fig. 3A). The band A and band B core structures (35) and the O-antigen are all seen to be present in the parental strains (Fig. 3A). However, O-antigen is absent from BB7865pgm and BB7866pgm, and the core structure is considerably truncated,

migrating faster than the band B of the parental strains. Complementation with *pgm* from the parental BB7865 strain restored the wild-type LPS phenotype to BB7865pgm (Fig. 3A). The influence of the *bvg* locus on the expression of PGM was analyzed. At 37°C and in the absence of chemical modulators such as MgSO₄, virulence factors are expressed. There exists a separate class of genes that are repressed by the *bvg* locus, including the genes encoding flagellum biosynthesis (1). This occurs with growth in modulating medium, i.e., containing MgSO₄, at lower temperatures (25°C). The size of the LPS molecule from the mutant strains is unaffected by growth under either modulating or nonmodulating conditions, as is the case for the wild type, indicating that the *bvg* locus elicits control only over the distal region of the molecule including the O-antigen. PGM and PGI are both required early in the pathway for production of sugar nucleotides destined for LPS




FIG. 4. Intracellular survival of *B. bronchiseptica* strains in J774.A1 cells at 2 and 24 h. Results shown are represented as mean percentages of CFU recovered of the respective parental strains. Error bars indicate the standard error of the mean.

synthesis. In fact they both catalyze the same substrate, glucose 1-phosphate, converting it to the respective precursors (Fig. 3B).

Intracellular survival of parental and PGM-deficient *B. bronchiseptica*. In vitro invasion and survival assays utilizing J774.A1 cells demonstrated a significantly reduced ability of the mutant strains to survive. Compared to the CFU of the respective parental strains, only 43% of BB7865pgm and 40% of BB7866pgm remained after 24 h (Fig. 4). Complementation of BB7865pgm with the wild-type *pgm* gene restored survival rates to levels above those observed in BB7865.

Highly reactive oxygen anion radicals are an effective intracellular defense mechanism employed by the host. Intracellular bacteria can utilize various enzymes such as SOD for the conversion of these radicals to more stable forms, i.e., O_2^- to H_2O_2 and O_2 . Of interest here is the effect of a compromised physical barrier to free radical attack; therefore, sensitivity of PGM mutants to oxidative stress was measured. BB7865pgm was notably more sensitive to paraquat (Table 2), a superoxide radical-generating compound, exhibiting a zone of inhibition of 8.5 mm on SS-C at 25°C and 7 mm on SS-X at 37°C compared to 0 mm for BB7865 under both conditions. Complementation of BB7865pgm with the wild-type *pgm* gene restored the wild-type phenotype. SOD activity levels remained unchanged for BB7865pgm (results not shown), suggesting a role for LPS as a physical barrier. Other phenotypes tested that are suggested to participate in intracellular survival within eukaryote cells are acid phosphatase (9) and urease (31). These phenotypes remained unaffected in the BB7865pgm mutant (results not shown).

TABLE 2. Sensitivity of *B. bronchiseptica* to oxidative stress as measured by disk diffusion of paraquat^a

| Strain | Zone of inhibition (mm) under condition: | | | |
|--|--|-----------|------------|-----------|
| | 30°C | | 37°C | |
| | SS-C | SS-X | SS-C | SS-X |
| BB7866 | 0 ± 0 | 0 ± 0 | 0 ± 0 | 0 ± 0 |
| BB7866pgm | 4.5 ± 0.5 | 3.5 ± 0.5 | 3.5 ± 0.5 | 1.5 ± 1.5 |
| BB7865 | 0 ± 0 | 0 ± 0 | 0 ± 0 | 0 ± 0 |
| BB7865pgm | 8.5 ± 1.5 | 3 ± 3 | 10.5 ± 0.5 | 7 ± 0 |
| BB7865pgm (pBBR1MCS-4/pgm ⁺) | 0 ± 0 | 0 ± 0 | 0 ± 0 | 0 ± 0 |

^a Values shown are means for three separate assays ± standard errors of the means.

TABLE 3. Sensitivity of *B. bronchiseptica* wild-type and mutant strains to cecropin P as measured by radial diffusion

| Strain | Inhibition zone ^a (mm) |
|--|-----------------------------------|
| BB7866 | 11 |
| BB7866pgm | 17 |
| BB7865 | 11.3 |
| BB7865pgm | 16.3 |
| BB7865pgm (pBBR1MCS-4/pgm ⁺) | 10.6 |

^a Inhibition zone refers to the diameter of the region of growth inhibition.

Resistance to the cationic peptide cecropin P. LPS is credited as being responsible for conferring some protection against antibiotics and serum (53) as a mode of protection from host defenses. Another naturally occurring class of molecules are the defensins. These are cationic peptides found in a wide variety of vertebrate and invertebrate organisms (15) on the surface of skin, trachea, and tongue among others (20, 43). The sensitivity of BB7865pgm to the defensin cecropin P in a radial diffusion assay was shown to be significantly increased ($P \leq 0.01$) compared to that of the wild-type strain (Table 3). Complementation of BB7865pgm with the wild-type *pgm* gene restored the wild-type phenotype in radial diffusion assays. It was also established that 90% of BB7865pgm, compared to BB7865 cells, were killed when incubated with a 50- μ g/ml solution of cecropin P for 1.5 h in liquid killing assays (results not shown).

Survival of BB7865pgm within the murine respiratory tract. In vitro survival assays demonstrated a marked reduction in the ability of the PGM mutant to invade or persist within J774.A1 cells (Fig. 4). This result led to the investigation of the effect the *B. bronchiseptica* *pgm* mutation would have within a murine respiratory infection model. Nonlethal doses of BB7865 or BB7865pgm were administered to BALB/c mice intranasally, and the numbers of CFU present in the lungs were measured at various time points following infection. Although the wild-type strain showed a classic pattern of infection (22), the mutant strain was unable to survive, being effectively cleared within 4 days. This was the result observed in two independent trials. The reduction in BB7865pgm CFU was found to be consistently significant from day 2 ($P \leq 0.05$). Mice infected with the wild-type strain still had an average of 1,000 CFU/lung persisting 35 days following inoculation (Fig. 5).




FIG. 5. In vivo persistence of wild-type BB7865 and the *pgm* mutant, BB7865pgm, in a murine respiratory model. Lungs were taken at different time intervals, and the number of viable bacteria per lung was determined. The results are averages of values for four mice.

DISCUSSION

A new gene cluster critically involved in the production of LPS in *B. bronchiseptica* is described here. The operon includes genes identified as encoding PGM and PGI, which are utilized in the synthesis of nucleotide sugars for inclusion into growing LPS molecules. Abolition of PGM activity will lead to the loss of glucose and all other components distal to the heptose residue of the *B. bronchiseptica* inner core (i.e., band A, band B, and O-antigen). Of further interest is the fact that the abolition of PGM activity renders the bacteria more susceptible to antimicrobial peptides and oxidative stress, reduces bacterial ability to survive within J774.A1 cells, and results in an inability to colonize the murine respiratory tract. Complementation of the PGM mutant *B. bronchiseptica pgm* with the wild-type *pgm* gene restored the wild-type condition for all phenotypes tested, indicating that the mutation of *pgm* was responsible for the altered phenotypes observed in this study.

The role played by the *bvg* locus in regard to the regulation of the PGM operon was investigated and was not found to be required for expression. The *bvg* locus has been shown in this study and in others (48) to influence the expression of LPS in response to a modulating environment (i.e., reduced temperature and increased sulfate anions). This is exemplified by the identical LPS profile of the *bvg*-negative mutant BB7866 and BB7865 grown in SS-C at 25°C compared to the contrasting LPS profile seen in BB7865 when grown in SS-X at 37°C. It has been observed that LPS expressed by *B. bronchiseptica* can change during an infection (17). This type of expression has been suggested to be a mechanism of adaptation to the host environment in other mucosal pathogens such as *P. aeruginosa* and *N. gonorrhoeae* (12, 49). The length of the O-antigen has been demonstrated to be an important factor for resistance to complement (8). It is therefore feasible that regulation of the LPS composition includes one form required for colonization or invasion and another for survival in a particular niche protected from host humoral defenses. The *bvg*-repressed form of LPS may also be advantageous to the cell during transmission between hosts. Other evidence existing for *bvg*-regulated LPS expression includes monoclonal antibodies specific for band B LPS of *B. pertussis*, which only react with *B. bronchiseptica* LPS in a *bvg*-repressed state (30).

However, *pgm* is not regulated by *bvg*. There is not a significant difference in the activity of the enzyme produced by *bvg*-positive or *bvg*-negative parental strains under any growth condition. This result is mirrored in the LPS profiles of the mutant strains that indicate the same size LPS molecule is produced for both, irrespective of growth conditions. A possible explanation for this observation is that the early core biosynthesis is not *bvg*-regulated. These genes are likely to be expressed as housekeeping genes rather than being controlled by the virulence regulator. Genes utilized for the synthesis of the LPS molecule distal to the core glucose are not required for growth but are utilized for virulence and thus may be regulated by the *bvg* locus. This hypothesis also seems likely given that the genes of the PGM operon are distinct from the other LPS biosynthesis genes, such as the *wlb* genetic locus responsible for band A biosynthesis and also involved in O-antigen production. Strengthening this point is the existence of the *waaA* and *waaC* genes (required for synthesis of the deep inner core), which are not incorporated in the *wlb* locus (3, 36).

The importance of LPS to pathogenesis can be inferred by the *B. bronchiseptica pgm* mutant. The results obtained from the murine respiratory infection model demonstrate that although lipid A and the deep inner core are sufficient for viability, this truncated form of LPS is inadequate for colonization

and survival of *B. bronchiseptica* in vivo. The absence of the O-antigen is likely to be a major factor in the behavior of BB7865 *pgm* mutant in vivo. The increased sensitivity to defensins is probably due to the lack of the O-antigen and may offer some reason as to why bacterial clearance was so efficient. The antimicrobial peptide tested in this study was of the cecropin class. These, like the defensins, are cationic peptides and play an important role in the innate immunity of the host respiratory tract. The mode of action of the peptides is the destabilization of the cellular membrane by binding with anionic phospholipids (29). The O-antigen of *B. bronchiseptica* is thought to constitute a protective barrier, thereby concealing the negative charge of the membrane (5).

Resistance to superoxide anions is an important factor in terms of bacterial intracellular survival. Evidence to suggest that LPS is in some way responsible for a level of protection from intracellular superoxide radicals may come from the fact that the mutants were more susceptible to paraquat despite SOD levels remaining at wild-type levels (results not shown). Again, the high charge of *B. bronchiseptica* O-antigen may be able to shield the cell from the destructive O_2^- radicals, at least at the concentration tested in this study.

The *bvg* regulation of the distal portion of the LPS molecule is in response to the environment in which the bacterium finds itself. The pathogen must be capable of expressing an O-antigen of the correct length and composition. Sequential mutagenesis of the LPS molecule from the distal region would be required to highlight which portion of the molecule is specifically required for pathogenesis.

ACKNOWLEDGMENTS

We acknowledge support from the Australian Research Council (grant A09231658). N. P. West is the recipient of a University of Wollongong postgraduate research award.

REFERENCES

- Akerley, B. J., D. M. Monack, S. Falkow, and J. F. Miller. 1992. The *bvgAS* locus negatively controls motility and synthesis of flagella in *Bordetella bronchiseptica*. *J. Bacteriol.* **174**:980-990.
- Allen, A., and D. Maskell. 1996. The identification, cloning and mutagenesis of a genetic locus required for lipopolysaccharide biosynthesis in *Bordetella pertussis*. *Mol. Microbiol.* **19**:37-52.
- Allen, A. G., T. Isobe, and D. J. Maskell. 1998. Identification and cloning of *waaF* (*rfaF*) from *Bordetella pertussis* and use to generate mutants of *Bordetella* spp. with deep rough lipopolysaccharide. *J. Bacteriol.* **180**:35-40.
- Allen, A. G., R. M. Thomas, J. T. Cadisch, and D. J. Maskell. 1998. Molecular and functional analysis of the lipopolysaccharide biosynthesis locus *wlb* from *Bordetella pertussis*, *Bordetella parapertussis* and *Bordetella bronchiseptica*. *Mol. Microbiol.* **29**:27-38.
- Banemann, A., H. Deppisch, and R. Gross. 1998. The lipopolysaccharide of *Bordetella bronchiseptica* acts as a protective shield against antimicrobial peptides. *Infect. Immun.* **66**:5607-5612.
- Beauchamp, C., and I. Fridovich. 1971. Superoxide dismutase: improved assays and an assay applicable to acrylamide gels. *Anal. Biochem.* **44**:276-287.
- Betsou, F., O. Sismeyro, A. Danchin, and N. Guiso. 1995. Cloning and sequence of the *Bordetella bronchiseptica* adenylate cyclase-hemolysin-encoding gene—comparison with the *Bordetella pertussis* gene. *Gene* **162**:165-166.
- Byrd, D. W., R. M. Roop, H. P. Veit, and G. G. Schurig. 1991. Serum sensitivity and lipopolysaccharide characteristics in *Bordetella bronchiseptica*, *B. pertussis* and *B. parapertussis*. *J. Med. Microbiol.* **34**:159-165.
- Chhatwal, G. S., M. J. Walker, H. R. Yan, K. N. Timmis, and C. A. Guzman. 1997. Temperature dependent expression of an acid phosphatase by *Bordetella bronchiseptica*—role in intracellular survival. *Microb. Pathog.* **22**:257-264.
- Cotter, P. A., M. H. Yuk, S. Mattoo, B. J. Akerley, J. Boschwitz, D. A. Relman, and J. F. Miller. 1998. Filamentous hemagglutinin of *Bordetella bronchiseptica* is required for efficient establishment of tracheal colonization. *Infect. Immun.* **66**:5921-5929.
- deLorenzo, V., M. Herrero, U. Jakubzik, and K. N. Timmis. 1990. Mini-Tn5 transposon derivatives for insertion mutagenesis, promoter probing, and chromosomal insertion of cloned DNA in gram-negative eubacteria. *J. Bacteriol.* **172**:6568-6572.

12. Deretic, V., M. Schurr, and H. Yu. 1995. *Pseudomonas aeruginosa*, mucoidy and the chronic infection phenotype in cystic fibrosis. *Trends Microbiol.* **3**: 351–356.
13. Di Fabio, J. L., M. Caroff, D. Karibian, J. C. Richards, and M. B. Perry. 1992. Characterization of the common antigenic lipopolysaccharide O-chains produced by *Bordetella bronchiseptica* and *Bordetella parapertussis*. *FEMS Microbiol. Lett.* **76**:275–281.
14. Ferry, N. S. 1910. A preliminary report of the bacterial findings in canine distemper. *Am. Vet. Rev.* **37**:499–504.
15. Ganz, T., and R. I. Lehrer. 1994. Defensins. *Curr. Opin. Immunol.* **6**:584–589.
16. Goodnow, R. A. 1980. Biology of *Bordetella bronchiseptica*. *Microbiol. Rev.* **44**:722–738.
17. Gueirard, P., K. Leblay, A. Lecoustumier, R. Chaby, and N. Guiso. 1998. Variation in *Bordetella bronchiseptica* lipopolysaccharide during human infection. *FEMS Microbiol. Lett.* **162**:331–337.
18. Gueirard, P., C. Weber, A. Lecoustumier, and N. Guiso. 1995. Human *Bordetella bronchiseptica* infection related to contact with infected animals: persistence of bacteria in host. *J. Clin. Microbiol.* **33**:2002–2006.
19. Guzmán, C. A., M. Rohde, M. Bock, and K. N. Timmis. 1994. Invasion and intracellular survival of *Bordetella bronchiseptica* in mouse dendritic cells. *Infect. Immun.* **62**:5528–5537.
20. Harder, J., J. Bartels, E. Christophers, and J. M. Schroder. 1997. A peptide from human skin. *Nature* **387**:861.
21. Hohn, B., and J. Collins. 1980. A small cosmid for efficient cloning of large DNA fragments. *Gene* **11**:291–298.
22. Jungnitz, H., N. P. West, M. J. Walker, G. S. Chhatwal, and C. A. Guzman. 1998. A second two-component regulatory system of *Bordetella bronchiseptica* required for bacterial resistance to oxidative stress, production of acid phosphatase, and *in vivo* persistence. *Infect. Immun.* **66**:4640–4650.
23. Kadmas, J. L., and C. R. H. Raetz. 1998. Enzymatic synthesis of lipopolysaccharide in *Escherichia coli*—purification and properties of heptosyltransferase 1. *J. Biol. Chem.* **273**:2799–2807.
24. Kaltwasser, H., and H. G. Schlegel. 1966. NADP-dependent coupled enzyme assay for urease and other ammonia producing systems. *Anal. Biochem.* **16**: 132–138.
25. Köplin, R., W. Arnold, B. Hötte, R. Simon, G. Wang, and A. Pühler. 1992. Genetics of xanthan production in *Xanthomonas campestris*: the *xanA* and *xanB* genes are involved in UDP-glucose and GDP-mannose biosynthesis. *J. Bacteriol.* **174**:191–199.
26. Kovach, M. E., P. H. Elzer, D. S. Hill, G. T. Robertson, M. A. Farris, R. M. Roop, and K. M. Peterson. 1995. Four new derivatives of the broad-host-range cloning vector pBBR1MCS, carrying different antibiotic-resistance cassettes. *Gene* **166**:175–176.
27. Lacey, B. W. 1960. Antigenic modulation of *Bordetella pertussis*. *J. Hyg.* **58**: 57–93.
28. Lesse, A. J., A. A. Campagnari, W. E. Bittner, and M. A. Apicella. 1990. Increased resolution of lipopolysaccharides and lipooligosaccharides utilizing tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis. *J. Immunol. Methods.* **126**:109–117.
29. Maloy, W. L., and U. P. Kari. 1995. Structure-activity studies on magainin and other host defence peptides. *Biopolymers* **37**:105–122.
30. Martin, D., M. S. Peppler, and B. R. Brodeur. 1992. Immunological characterization of the lipooligosaccharide B band of *Bordetella pertussis*. *Infect. Immun.* **60**:2718–2725.
31. McMillan, D. J., M. Shojaei, G. S. Chhatwal, C. A. Guzman, and M. J. Walker. 1996. Molecular analysis of the Bvg-repressed urease of *Bordetella bronchiseptica*. *Microb. Pathog.* **21**:379–394.
32. Miller, V. L., and J. J. Mekalanos. 1988. A novel suicide vector and its use in construction of insertion mutations: osmoregulation of outer membrane proteins and virulence determinants in *Vibrio cholerae* requires *toxR*. *J. Bacteriol.* **170**:2575–2583.
33. Monack, D., B. Arico, R. Rappouli, and S. Falkow. 1989. Phase variants of *Bordetella bronchiseptica* arise by spontaneous deletions in the *vir* locus. *Mol. Microbiol.* **3**:1719–1728.
34. Onishi, H. R., B. A. Pelak, L. S. Gerckens, L. L. Silver, F. M. Kahan, M. H. Chen, A. A. Patchett, S. M. Galloway, S. A. Hyland, M. S. Anderson, and C. R. H. Raetz. 1996. Antibacterial agents that inhibit lipid A biosynthesis. *Science.* **274**:980–982.
35. Peppler, M. S. 1984. Two physically and serologically distinct lipopolysaccharide profiles in strains of *Bordetella pertussis* and their phenotype variants. *Infect. Immun.* **43**:224–232.
36. Preston, A., A. G. Allen, J. Cadisch, R. Thomas, K. Stevens, C. M. Churcher, K. L. Badcock, J. Parkhill, B. Barrell, and D. J. Maskell. 1999. Genetic basis for lipopolysaccharide O-antigen biosynthesis in *Bordetellae*. *Infect. Immun.* **67**:3763–3767.
37. Preston, A., R. E. Mandrell, B. W. Gibson, and M. A. Apicella. 1996. The lipooligosaccharides of pathogenic Gram-negative bacteria. *Crit. Rev. Microbiol.* **22**:139–180.
38. Priester, U., R. Simon, and A. Pühler. 1984. Cloning with cosmids, p. 190–221. *In A. Pühler and K. N. Timmis (ed.), Advanced molecular genetics.* Springer-Verlag, Berlin, Germany.
39. Rietschel, E. T., T. Kirikae, F. U. Schade, U. Mamat, G. Schmidt, H. Loppnow, A. J. Ulmer, U. Zahringer, U. Seydel, F. Dipadova, M. Schreier, and H. Brade. 1994. Bacterial endotoxin—molecular relationships of structure to activity and function. *FASEB J.* **8**:217–225.
40. Roop, II, R. M., H. P. Veit, R. J. Sinsky, S. P. Veit, E. L. Hewlett, and E. T. Kornegay. 1987. Virulence factors of *Bordetella bronchiseptica* associated with the production of infectious atrophic rhinitis and pneumonia in experimentally infected neonatal swine. *Infect. Immun.* **55**:217–222.
41. Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. *Molecular cloning. A laboratory manual*, 2nd ed. Cold Spring Harbor Press, Cold Spring Harbor, N.Y.
42. Sandlin, R. C., and D. C. Stein. 1994. Role of phosphoglucomutase in lipooligosaccharide biosynthesis in *Neisseria gonorrhoeae*. *J. Bacteriol.* **176**: 2930–2937.
43. Schonwetter, B. S., E. D. Stolzenberg, and M. A. Zasloff. 1995. Epithelial antibiotics induced at sites of inflammation. *Science* **267**:1645–1648.
44. Smith, A. M., and M. J. Walker. 1996. Transfer of a pertussis toxin expression locus to isogenic Bvg-positive and Bvg-negative strains of *Bordetella bronchiseptica* using an *in vivo* technique. *Microb. Pathog.* **20**:263–273.
45. Stainer, D., and M. Scholte. 1971. A simple chemically defined medium for the production of phase I *Bordetella pertussis*. *J. Gen. Microbiol.* **63**:211–220.
46. Tamim, F., C. Girault, V. Chevron, M. Pestel, and G. Bonmarchand. 1996. *Bordetella bronchiseptica* pneumonia with shock in an immunocompetent patient. *Scand. J. Infect. Dis.* **28**:197–198.
47. Tsai, C. M., and C. E. Frasch. 1982. A sensitive silver stain for detecting lipopolysaccharides in polyacrylamide gels. *Anal. Biochem.* **119**:115–119.
48. van den Akker, W. M. R. 1998. Lipopolysaccharide expression within the genus *Bordetella*—influence of temperature and phase variation. *Microbiology* **144**:1527–1535.
49. Van Putten, J. P. 1993. Phase variation of lipopolysaccharide interconversion of invasive and immuno-resistant phenotypes of *Neisseria gonorrhoeae*. *EMBO J.* **12**:4043–4051.
50. Walker, K. E., and A. A. Weiss. 1994. Characterization of the dermonecrotic toxin in members of the genus *Bordetella*. *Infect. Immun.* **62**:3817–3828.
51. Walker, M. J., R. G. Birch, and J. M. Pemberton. 1988. Cloning and characterisation of an albicidin resistance gene from *Klebsiella oxytoca*. *Mol. Microbiol.* **2**:443–454.
52. Westermeyer, R. 1993. *Electrophoresis in practice.* VCH Verlagsgesellschaft, Weinheim, Germany.
53. Wood, A. C., N. J. O. Oldfield, C. A. Dwyer, and J. M. Ketley. 1999. Cloning, mutation and distribution of a putative lipopolysaccharide biosynthesis locus in *Campylobacter jejuni*. *Microbiol.* **145**:379–388.
54. Woolfrey, B. F., and J. A. Moody. 1991. Human infections associated with *Bordetella bronchiseptica*. *Clin. Microbiol. Rev.* **4**:243–255.
55. Yanisch-Perron, C., J. Viegria, and J. Messing. 1985. Improved M13 phage cloning vectors and host strains: nucleotide sequences of the M13mp18 and pUC19 vectors. *Gene* **33**:103–119.
56. Zhou, D. G., D. S. Stephens, B. W. Gibson, J. J. Engstrom, C. F. Mcallister, F. K. N. Lee, and M. A. Apicella. 1994. Lipooligosaccharide biosynthesis in pathogenic *Neisseria*—cloning, identification, and characterization of the phosphoglucomutase gene. *J. Biol. Chem.* **269**:11162–11169.